Physician profile
Henry H Wang
NPI 1497757405
$19,998.61
in general payments reported to CMS, 2019-2025
57 companies · $8,664 in 2025
The $8,664 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,692 · 2020: $711 · 2021: $1,690 · 2022: $2,460 · 2023: $2,229 · 2024: $2,553 · 2025: $8,664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,779 · Consulting Fee: $5,000 · Travel and Lodging: $561 · Education: $106.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,778.65 |
| Consulting Fee | $5,000.00 |
| Travel and Lodging | $561.15 |
| Education | $105.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agios Pharmaceuticals, INC. | $5,942.75 | 2024-2025 | Pyrukynd |
| Glaxosmithkline, LLC. | $1,443.65 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,386.73 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $988.75 | 2021-2025 | Vraylar, Rinvoq, Linzess |
| Amgen INC. | $925.61 | 2019-2025 | Repatha, Otezla, Evenity |
| Mylan Specialty L.P. | $859.46 | 2019-2024 | Yupelri, Yupelri |
| Radius Health, INC. | $736.26 | 2019-2025 | Tymlos |
| Amarin Pharma, INC. | $677.93 | 2019-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $616.52 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $613.73 | 2023-2025 | Rexulti |
| Novo Nordisk INC | $609.81 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $392.98 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $389.16 | 2019-2024 | Xarelto |
| Lilly USA, LLC | $356.41 | 2021-2025 | Jardiance, Mounjaro, Emgality |
| Astellas Pharma US INC | $296.91 | 2019-2025 | Veozah, Myrbetriq |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Henry Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.